Acetylcholine Receptor Modulating Antibody
Test Mnemonic
ACEMOD
CPT Codes
- 86043 - QTY (1)
LOINC ®
30192-9
Performing Laboratory
ARUP
FDA Category
Laboratory Developed Test
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL | Serum | SST (Gold) | Refrigerated | Remove serum from cells ASAP. |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.3 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | After separation from cells: 2 hours |
| Refrigerated | After separation from cells: 2 weeks |
| Frozen | After separation from cells: 1 year (Avoid multiple freeze/thaw cycles) |
Days Performed
Sun - Fri
Turnaround Time
3 - 8 days
Reference Range
| Acetylcholine Receptor Modulating Ab | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Normal | Negative: 0 - 45 | % Modulating | Normal | Positive: >= 46 | % Modulating |
Special Info
Severely lipemic, contaminated or hemolyzed specimens are unacceptable.
Clinical Info
Approximately 85 - 90% of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10 - 15% of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.